|New Threads Only:|
|New Threads & Replies:|
Forum List » Business News and Headlines|
SEC Filings, Earing Reports, Press Releases
Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Results
Posted by: gurufocus (IP Logged)
Date: July 31, 2009 07:02PM
Press Release: Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that it plans to report its second quarter 2009 financial results on Friday, August 7, 2009 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST (11:00 a.m. EST), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the second quarter 2009 and provide a product pipeline update.
To participate by telephone please dial 888-256-9044 for domestic callers or 706-643-5585 for international callers and provide the conference ID # 22806199. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme’s Web site for seven days. A telephone replay will be available by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company\'s portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets and with Baxter BioScience to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID™. The product candidates in Halozyme’s research pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.
Stocks Discussed: HALO,